Inotek Pharmaceuticals Corporation

Release Summary

Inotek Pharmaceuticals Corporation (NASDAQ: ITEK) today announced top-line results of MATrX-1, the first pivotal Phase 3 trial of trabodenoson for glaucoma.

Inotek Pharmaceuticals Corporation